In Vitro and in Vivo Effects of Hemodilution on Kaolin-based Activated Clotting Time Predicted Heparin Requirement Using a Heparin Dose-response Technique

Overview

Journal J Anesth

Specialty Anesthesiology

Date 2016 Aug 10

PMID 27502398

Citations 1

Authors

Junko Ichikawa

Satoshi Hagihira

Testu Mori

Mitsuharu Kodaka

Keiko Nishiyama

Makoto Ozaki

Makiko Komori

Affiliations

Soon will be listed here.

Abstract

Purpose: The heparin dose-response (HDR) technique is based on activated clotting time (ACT) response to a fixed-dose heparin bolus, which varies substantially among patients. It is unclear, however, whether hemodilution-associated reductions in coagulation and anticoagulation factors affect the HDR slope.

Methods: For in vitro hemodilution, aliquots of whole blood from healthy volunteers were diluted 9:1 and 8:2 v/v with normal saline. For in vivo hemodilution, a prospective observational study was performed on 46 patients who underwent elective cardiovascular surgery with or without cardiopulmonary bypass. HDR slope, antithrombin (AT) activity, complete blood count, and other coagulation parameters were compared after induction of anesthesia and after hemodilution with 500 ml of intravenous fluid.

Results: In vitro 10 and 20 % hemodilution significantly increased the HDR slope relative to baseline, reducing the heparin requirement. Hemodilution of heparinized samples significantly prolonged ACT, whereas there was no significant change in non-heparinized blood. The percent changes in fibrinogen and AT activity were significantly greater at 20 % than those of the other coagulation variables. In vivo, hemodilution significantly increased the HDR slope and reduced heparin requirement. The percent change in fibrinogen due to hemodilution was significantly greater than the change in AT activity. Target ACTs of 300 and 450 s were not achieved in 83.3 and 53.8 % of patients, respectively.

Conclusion: In vitro and in vivo hemodilution significantly increased the HDR slope and reduced the requirement for heparin. In vitro, the HDR slope did not change in parallel but became steeper, depending on the degree of hemodilution.

Citing Articles

Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors.

Nilsson S, Appelblad M, Svenmarker S J Extra Corpor Technol. 2020; 52(3):212-217.

PMID: 32981959 PMC: 7499231. DOI: 10.1182/ject-2000005.

References

Linden M, Gibbs N, Bremner M, Schneider M, Erber W . The effect of haemodilution on antithrombin concentration during cardiac surgery. Anaesth Intensive Care. 2005; 32(2):219-23. DOI: 10.1177/0310057X0403200209. View

Olson S, BJORK I, Sheffer R, Craig P, SHORE J, CHOAY J . Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992; 267(18):12528-38. View

MURANO G, Williams L, Aronson D, King C . Some properties of antithrombin-III and its concentration in human plasma. Thromb Res. 1980; 18(1-2):259-62. DOI: 10.1016/0049-3848(80)90190-5. View

Tollefsen D, Majerus D, Blank M . Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem. 1982; 257(5):2162-9. View

Huyzen R, Harder M, Huet R, Boonstra P, Brenken U, van Oeveren W . Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. J Cardiothorac Vasc Anesth. 1994; 8(2):153-6. DOI: 10.1016/1053-0770(94)90054-x. View

Bull B, HUSE W, Brauer F, Korpman R . Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975; 69(5):685-9. View

Darlington D, Delgado A, Kheirabadi B, Fedyk C, Scherer M, Pusateri A . Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro. J Trauma. 2011; 71(5):1152-63. DOI: 10.1097/TA.0b013e318215178c. View

Hirsh J, Warkentin T, Shaughnessy S, Anand S, Halperin J, Raschke R . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(1 Suppl):64S-94S. DOI: 10.1378/chest.119.1_suppl.64s. View

Freedman M . Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol. 1992; 32(7):584-96. DOI: 10.1002/j.1552-4604.1992.tb05765.x. View

10.

Abildgaard U . Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis. 1993; 23 Suppl 1:103-6. DOI: 10.1159/000216918. View

11.

Srivastava A, Banerjee A, Misra B, Minhas H, Virmani S . Does hemodilution by the crystalloid priming solution derange the efficacy of anticoagulation during cardiopulmonary bypass?. J Card Surg. 2008; 23(3):239-45. DOI: 10.1111/j.1540-8191.2007.00535.x. View

12.

Ruttmann T, James M, Aronson I . In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth. 1998; 80(5):612-6. DOI: 10.1093/bja/80.5.612. View

13.

Vicente C, He L, Pavao M, Tollefsen D . Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood. 2004; 104(13):3965-70. DOI: 10.1182/blood-2004-02-0598. View

14.

Ruttmann T, James M, Viljoen J . Haemodilution induces a hypercoagulable state. Br J Anaesth. 1996; 76(3):412-4. DOI: 10.1093/bja/76.3.412. View

15.

Jobes D, Aitken G, Shaffer G . Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995; 110(1):36-45. DOI: 10.1016/S0022-5223(05)80007-8. View

16.

Ng K, Lo J . The development of hypercoagulability state, as measured by thrombelastography, associated with intraoperative surgical blood loss. Anaesth Intensive Care. 1996; 24(1):20-5. DOI: 10.1177/0310057X9602400104. View

17.

Raymond P, Ray M, Callen S, Marsh N . Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003; 18(5):269-76. DOI: 10.1191/0267659103pf672oa. View

18.

Culliford A, Gitel S, Starr N, Thomas S, Baumann F, Wessler S . Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981; 193(1):105-11. PMC: 1345010. DOI: 10.1097/00000658-198101000-00017. View

19.

MONKHOUSE F . Relationship between antithrombin and thrombin levels in plasma and serum. Am J Physiol. 1959; 197:984-8. DOI: 10.1152/ajplegacy.1959.197.5.984. View

20.

Maaroufi R, Jozefowicz M, Tapon-Bretaudiere J, Fischer A . Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin. Biomaterials. 1997; 18(3):203-11. DOI: 10.1016/s0142-9612(96)00125-1. View